Brief: Biovica: DiviTumTKA In Early Treatment Resistance Trial

Biovica International AB

18/01/2021 07:03

Jan 18 (Reuters) - Biovica International AB  BIOVICb.ST :
    * BIOVICA’S DIVITUM®TKA IN EARLY TREATMENT RESISTANCE TRIAL
    * DIVITUM®TKA HAS BEEN SELECTED TO BE INCLUDED IN NEW
PROSPECTIVE
CLINICAL STUDY TIRESIAS
    * AIM IS INVESTIGATING IF DIVITUM TKA CAN BE USED TO
IDENTIFY
EARLY RESISTANCE TO TREATMENT BY A CDK4/6 INHIBITOR IN
COMBINATION WITH AN AROMATASE INHIBITOR IN BREAST CANCER
PATIENTS

Source text for Eikon:  ID:nMFN2PjzG9 
Further company coverage:  BIOVICb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;  +48 587696600;))